Telix Pharmaceuticals Ltd (TLX)
A
Pipeline Grade
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
GALLIUM GA-68 GOZETOTIDE
ILLUCCIX |
APPROVED | Advanced Cancer, Advanced Renal Cell Carcinoma, Advanced Solid Tumor, BCR Prostate Carcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate, Bladder Cancer, Bladder Urothelial Carcinoma, Bone Metastases in Subjects With Advanced Cancer, Bone Pain, Brain Neoplasms, Carcinoma of the Prostate, Carcinoma, Renal Cell, ccRCC, Cervical Cancer, Cholangiocarcinoma, Clear Cell Renal Carcinoma, Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma (ccRCC), Colorectal Cancer, Diagnostic Imaging, Elevated PSA, Epithelial Ovarian Cancer, Esophageal Cancer, Gastric Adenocarcinoma, Gastric Cancer, Glioblastoma, Glioblastoma (GBM), Glioblastoma Multiform, Glioblastoma Multiforme, Glioblastoma Multiforme (GBM) WHO Grade IV, Glioblastoma Multiforme, Adult, Glioma, Glioma (Any Grade) in the Brain, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Malignant Mesothelioma (MM), Metastatic Bone Tumor, Metastatic Castration Resistant Prostate Cancer, Metastati |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04402151 | Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-I... | PHASE2 | Recruiting | 50 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.